Commentary on 'Targeting metastasis-initiating cells through the fatty acid receptor CD36' by Pascual et al., Nature 2017.
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CD36 is a glycosylated 88 kD integral membrane protein also commonly referred to as GPIV (glycoprotein IV) or FAT (fatty acid translocase). It was discovered in platelets 40 years where it showed a high affinity for collagen type I and IV thereby contributing to platelet adhesion and further activation. 2 Since then, it has been detected in the surface of a variety of cell types including adipocytes, myocytes, monocytes/ macrophages, microvascular endothelial cells, hepatocytes, and some epithelia, being involved in the modulation of multiple cellular functions. It is well established that CD36 facilitates the uptake of long-chain fatty acids into adipocytes, the heart and the skeletal muscle. In this regard, adipose tissue expression of CD36 has been shown to correlate with body mass index suggesting a potential relevance in obesity (a key cardiovascular risk factor). Likewise, although cardiac CD36 mediates fatty acid uptake for energy production, enhanced CD36 expression in myocytes has been shown to favour heart lipotoxicity. 3, 4 CD36 has also shown to exert other functions related with the development of cardiovascular disease also related with lipid uptake. As such, by working as a scavenger receptor for oxidized low-density lipoprotein particles in macrophagesand vascular smooth muscle cells, CD36 has shown to induce foam cell formation favouring atherosclerotic lesions progression. 5, 6 In the Nature article, the group of Salvador Aznar Benitah 1 provides evidence of another function regulated by CD36 through fatty acid uptake, metastasis progression. The authors firstly demonstrated in human oral carcinomas that culprit cells behind oral cancers induce high levels of CD36 which, in turn, trigger a signaling cascade involved in the conversion of fatty acids to energy production (i.e. ATP). Interestingly, they evidence that CD36 metastatic potential is dependent on its lipid metabolism. As such, administration of a highfat diet to mice induces the development of more aggressive oral cancers and more aggressive metastasis in a CD36-dependent manner. In counterpart, alteration of CD36 activity leads to intracellular accumulation of lipids and the consequent lipotoxic cell death (anti-metastatic effects). Based on these findings, the authors postulate that CD36þ cells may take advantage of this feature to take the amount of energy required to anchor and survive at sites distant from the primary tumour. The authors further demonstrate in vivo that infusion of these CD36þ cells to non-metastatic tumours induces metastasis, whereas, conversely, CD36 depletion by intraperitoneal administration of two different CD36-neutralizing antibodies not only prevents tumour metastasis but also largely regress those metastatic tumours that had already been developed. These anti-metastatic properties are observed without affecting primary tumour formation and without concomitant side effects. Finally, in order to determine whether these remarkable findings reported in rodents may have any clinical implication the authors perform a thorough research on the publicly available data and find a strong correlation between CD36 production in human tumours and highly aggressive cancers and poor disease-free survival further supporting, at a human level, an association between CD36 expression and metastasis progression. So far, multiple studies have linked CD36 with cancer because of its anti-angiogenic activity. As such, thrombospondin interaction with CD36 present in microvascular cells has shown to induce apoptosis of endothelial cells thereby preventing the development of new vessels. 7 Yet, the work by Pascual et al. proves that CD36 may contribute to metastasis via abnormal tissue fatty acid handling rather than by modulating angiogenesis. Intriguingly, these findings are in line with the contribution of CD36 in the progression of cardiovascular disease. Given that lipid interaction with CD36 seems to play a key role in the progression of the most highly prevalent disease (cardiovascular, cancer, and obesity) efforts of different research fields should focus on the discovery and testing of therapeutic strategies addressed to selectively target CD36 with the aim to modulate its metabolic function. To that end, however, because of the ubiquitous nature and different functions attributed to CD36, there is a need to better understand cell-specific CD36 regulation.
